Zofran in nausea and vomiting prevention caused by Cytostatic drugs in
patients with carcinoma of the testicle and urinary bladder
Article published in Urologia Polska 1993/46/4.
authors
-
Jerzy Świerż, Bronisław Stawarz
- Z Kliniki Urologii Centralnego Szpitala Klinicznego WAM w Warszawie
Kierownik Kliniki: Prof. dr hab. med. B. Stawarz
summary
- Effectiveness and toxicity evaluation is presented in ondansetron (zofran) treatment of
- nausea and vomiting caused by Cytostatic drugs. In 38 patients (79%) the complete lack of
- nausea and vomiting was obtained. Drug tolerance was good. Of essential side effects
- constipation (38%) and headaches (31%) were found. Authors conclude that ondansetron is an
- effective and safe drug against nausea and vomiting followed by cytostatics.
references
- 1.Brown G., Pees D., BrysonJ., Freeman A.: The effectiveness of single intravenous dose of ondansetron. Oncology 1992, 49, 273. —
- 2. Depiewe A., Lebean B., d\\\'Allens H.: A Comparison of ondansetron with alizapride plus methylprednisolone in the control of cisplatin induced emesis. Oncology, 1992, 42, 305. —
- 3. Finn A.: Toxicity and side effect of ondansetron. Semin. Oncol., 1992, 19, 53. —
- 4. Freeman A., Cunningham K., Tyers M.: Selectivity of 5HT3 receptor antagonists and antiemetic mechanisms of action. Anticancer Drugs, 1992, 3, 79. —
- 5. GandaraD., Harvey W., Monaghan G., Perez E., Stokes C: The delayed emeisi syndrome from cisplatin, phase III evaluation of ondansetron versus placebo. Semin. Oncol., 1992,19,67. —
- 6. Hainsworth J.\\\\ The use of ondansetron in patiens receiving multipleday cisplatin regimens. Semin. Oncol., 1992, 19, 48. —
- 7. Jurgens H., McQuade B.\\\\ Ondansetron as prophylaxis for chemotherapy and radiotherapy induced emesis in children. Oncology, 1992, 49, 279. —
- 8. KrisM., Tyson L., Cark R., Grralla R.: Oral ondansetron for the control of delayed emesis after cisplatin. Cancer, 1992, 70, 1012. —
- 9. Legha S., Hodges C, Ring S.: Efficacy of ondansetron against nausea and vomiting caused by dacarbazine-containing chemotherapy. Cancer, 1992, 70, 2018. —
- 10. Morena J., Rosek R., Abad A., Barnadas A., Carles J.: Comparison of three protracted antiemetic regimens for the control of delayed emesis in cisplatin treated patients. Eur. J. Cancer, 1992, 28, 1344.
- 11.Seynaeve C, Mulder P., Lane A., Liessum P., Verweij J.: The 5TH3 receptor antagonist ondansetron reestablishes control in refractory emesis induced by non-cisplatin chemotherapy. Clin. Oncol. R. Coll. Radiol., 1991, 3, 199. —
- 12. Soukop M., McQuade B., Hunter E., Stewart A., Kaye S.: Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for brest cancer. Oncology, 1992, 49, 295. —
- 13. Tyres M., Freeman A.: Mechanism of antiemetic activity of 5HT3 receptor antagonists. Oncology, 1992, 49, 263.
correspondence
dr med. Jerzy Swierż,
Klinika Urologii, Centralny Szpital Kliniczny WAM
00-909 Warszawa, ul. Szaserów 128
|